BSX - Boston Scientific Corporation

NYSE - NYSE Delayed Price. Currency in USD
44.28
+1.08 (+2.50%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close43.20
Open43.20
Bid44.00 x 800
Ask44.28 x 3200
Day's Range43.14 - 44.31
52 Week Range34.35 - 46.62
Volume15,417,119
Avg. Volume6,823,669
Market Cap61.718B
Beta (5Y Monthly)0.79
PE Ratio (TTM)57.51
EPS (TTM)0.77
Earnings DateFeb 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.62
  • Boston Scientific Gets a Boost From New Products, Buyouts
    Zacks

    Boston Scientific Gets a Boost From New Products, Buyouts

    Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.

  • 3 Medical Product Stocks Set to Beat This Earnings Season
    Zacks

    3 Medical Product Stocks Set to Beat This Earnings Season

    Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

  • Boston Scientific Stock Dips on Dull Preliminary Q4 Results
    Zacks

    Boston Scientific Stock Dips on Dull Preliminary Q4 Results

    Boston Scientific's (BSX) organic revenue growth will likely lag expectations for both the fourth quarter and 2019.

  • Medtech CEO Bullish After Preliminary Fourth-Quarter Report Disappoints
    Investor's Business Daily

    Medtech CEO Bullish After Preliminary Fourth-Quarter Report Disappoints

    Boston Scientific preliminarily announced disappointing fourth-quarter sales on Tuesday, sending BSX stock into a tailspin. The biggest shortfall came from cardiac rhythm management.

  • HRC or BSX: Which Is the Better Value Stock Right Now?
    Zacks

    HRC or BSX: Which Is the Better Value Stock Right Now?

    HRC vs. BSX: Which Stock Is the Better Value Option?

  • MarketWatch

    Boston Scientific's stock falls after downbeat sales update

    Shares of Boston Scientific Corp. dropped 6.3% in premarket trading Tuesday, after the medical technology company provided a fourth-quarter sales outlook that was below expectations. On a preliminary basis, sales rose 13.4% to $2.90 billion, below the FactSet consensus of $2.93 billion, as MedSurg revenue rose 9.8%, Rhythm and Neuro grew 3.5%, Cardiovascular increased 18.7% and medical devices rose 11.2%. The company said it is still closing its books for the quarter, but estimates it will report adjusted earnings per share within its previously issued guidance range of 42 cents to 45 cents; the FactSet consensus was 44 cents. The stock has run up 19.8% over the past three months through Monday, while the SPDR Health Care Select Sector ETF has rallied 14.0% and the S&P 500 has gained 10.9%.

  • Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2019
    PR Newswire

    Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2019

    Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents growth of approximately 13.4 percent on a reported basis, compared to the company's guidance range of 13 to 15 percent; approximately 14.1 percent on an operational1 basis, compared to the company's guidance range of 14 to 16 percent; and approximately 7.3 percent on an organic2 basis, compared to the company's guidance range of 8 to 9 percent, all compared to the prior year period.

  • Boston Scientific Announces January Conference Schedule and Conference Call Discussing Fourth Quarter 2019 Results
    PR Newswire

    Boston Scientific Announces January Conference Schedule and Conference Call Discussing Fourth Quarter 2019 Results

    Boston Scientific Corporation (NYSE: BSX) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California. Mike Mahoney, chairman and chief executive officer, will present at approximately 8:00 a.m. PST / 11:00 a.m. EST. At 8:30 a.m. PST / 11:30 a.m. EST, Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, Ian Meredith, MD, executive vice president and global chief medical officer, and Susie Lisa, vice president, Investor Relations, in a question-and-answer session with the host analyst and audience members.

  • I Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
    Simply Wall St.

    I Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease

    Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

  • Court orders Boston Scientific to complete $275M acquisition
    American City Business Journals

    Court orders Boston Scientific to complete $275M acquisition

    Boston Scientific Corp. could be forced to go through with a $275 million acquisition that the Marlborough-based medical device giant had abandoned following a fraud investigation.

  • Boston Scientific Corporation (BSX) vs. Top 20 Hedge Fund Stocks in 2019
    Insider Monkey

    Boston Scientific Corporation (BSX) vs. Top 20 Hedge Fund Stocks in 2019

    We are still in an overall bull market and many stocks that smart money investors were piling into surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57% each. Hedge funds' top 3 stock picks returned 44.6% this year and beat the S&P 500 ETFs by […]

  • Signature Select Canadian Fund's Top 5 Buys
    GuruFocus.com

    Signature Select Canadian Fund's Top 5 Buys

    Fund’s top buy is in gold ETF. It also enters a small stake in Buffett’s conglomerate Continue reading...

  • Benzinga

    The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...

  • Boston Scientific's First Single-Use Duodenoscope Gets FDA Nod
    Zacks

    Boston Scientific's First Single-Use Duodenoscope Gets FDA Nod

    Boston Scientific's (BSX) EXALT Model D single-use duodenoscope gets clearance from the FDA for use in ERCP procedures.

  • Boston Scientific Hits New 52-Week High: What's Driving it?
    Zacks

    Boston Scientific Hits New 52-Week High: What's Driving it?

    Boston Scientific (BSX) is optimistic about sustaining the growth momentum on recent positive developments.

  • Boston Scientific Receives FDA Clearance For World's First Single-Use Duodenoscope, EXALT™ Model D
    PR Newswire

    Boston Scientific Receives FDA Clearance For World's First Single-Use Duodenoscope, EXALT™ Model D

    Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model D Single-Use Duodenoscope for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures. The EXALT Model D Duodenoscope is the first and only FDA cleared single-use (disposable) duodenoscope on the market and was granted Breakthrough Device Designation from the FDA to ensure patients and healthcare providers have timely access to this device.

  • The 13 Best Health-Care Stocks to Buy for 2020
    Kiplinger

    The 13 Best Health-Care Stocks to Buy for 2020

    One of the most attractive reasons to invest in health-care stocks continues to be the world's aging population.The United Nations says people age 65 and older are the fastest-growing age group worldwide. It estimates that by 2050, one out of every six people will be 65 or older, accounting for 16% of the planet's total population, up from 9% in 2011. That figure is even larger in Europe and North America, where the U.N. predicts the number will be closer to 25%. The demand for health-care products and services should only increase as a result.Yes, health-care stocks will be coming off a weak 2019. Through mid-November, the S&P; 500 was sitting on nearly 25% gains, while the sector had improved by roughly half that. They'll also have to contend with uncertainty regarding the future of health care as the 2020 presidential election approaches. But don't sleep on the space in the year ahead.For one, health-care stocks tend to outperform during periods of economic weakness. For instance, the Health Care Select Sector SPDR Fund (XLV) delivered a 39.6% total loss (share price plus dividends) during the 2007-09 bear market - more than 15 percentage points better than the S&P; 500\. Thus, headlines warning of an economic slowdown or even a recession in 2020 actually bode well for the sector.Also, health care has traded at a price-to-earnings ratio more expensive than the overall market more often than not over the past 20 years. However, according to the Charles Schwab Center for Research, the sector's P/E currently is cheaper than the S&P; 500, providing a better buying opportunity.Here, then, are the 13 best health-care stocks to buy for 2020, including a couple of funds for investors who want to diversify. SEE ALSO: Every Warren Buffett Stock Ranked: The Berkshire Hathaway Portfolio

  • South Texas Military Contracting Roundup: more than $46M in contracts awarded
    American City Business Journals

    South Texas Military Contracting Roundup: more than $46M in contracts awarded

    This week's military contracting roundup features three contract notices for food distribution, staffing of certified registered nurse anesthetists and neurostimulator implantable devices, as well as solicitations for four contracts at Joint Base San Antonio.

  • Calculating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
    Simply Wall St.

    Calculating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

    Does the December share price for Boston Scientific Corporation (NYSE:BSX) reflect what it's really worth? Today, we...

  • Boston Scientific's Watchman Implant Study Results Encourage
    Zacks

    Boston Scientific's Watchman Implant Study Results Encourage

    These study results are expected to be a major breakthrough for Boston Scientific's (BSX) Cardiovascular segment.

  • Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​
    American City Business Journals

    Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​

    The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.

  • Urbem's 'Wonderful Business' Series: Intuitive Surgical
    GuruFocus.com

    Urbem's 'Wonderful Business' Series: Intuitive Surgical

    A near-monopoly pioneer in a fast-growing space Continue reading...

  • Is Boston Scientific Corporation (BSX) A Good Stock To Buy?
    Insider Monkey

    Is Boston Scientific Corporation (BSX) A Good Stock To Buy?

    While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the third quarter and hedging or reducing many of […]

  • Boston Scientific (BSX) Up 4.5% Since Last Earnings Report: Can It Continue?
    Zacks

    Boston Scientific (BSX) Up 4.5% Since Last Earnings Report: Can It Continue?

    Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.